Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States

被引:223
作者
Doern, GV [1 ]
Ferraro, MJ [1 ]
Brueggemann, AB [1 ]
Ruoff, KL [1 ]
机构
[1] HARVARD UNIV, MASSACHUSETTS GEN HOSP, SCH MED, BOSTON, MA USA
关键词
D O I
10.1128/AAC.40.4.891
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Three hundred fifty-two blood culture isolates of viridans group streptococci obtained from 43 U,S, medical centers during 1993 and 1994 were characterized, Included were 48 isolates of ''Streptococcus milleri,'' 219 S. mitis isolates, 29 S, salivarius isolates, and 56 S. sanguis isolates, High-level penicillin resistance (MIG, greater than or equal to 4.0 mu g/ml) was noted among 13.4% of the strains; for 42.9% of the strains, penicillin MICs were 0.25 to 2.0 mu g/ml (i,e,, intermediate resistance), In general, amoxicillin was slightly more active than penicillin, The rank order of activity for five cephalosporins versus viridans group streptococci was cefpodoxime = ceftriaxone > cefprozil = cefuroxime much greater than cephalexin, The percentages of isolates resistant (MIC, greater than or equal to 2 mu g/ml) to these agents were 15, 17, 18, 20, and 96, respectively, The rates of resistance to erythromycin, tetracycline, and trimethoprimsulfamethoxazole were 12 to 38%, Resistance to either chloramphenicol or ofloxacin was uncommon (i,e., <1%). In general, among the four species, S, mitis was the most resistant and ''S, milleri'' was the most susceptible.
引用
收藏
页码:891 / 894
页数:4
相关论文
共 15 条
[1]   BACTEREMIA DUE TO VIRIDANS STREPTOCOCCUS IN NEUTROPENIC PATIENTS WITH CANCER - CLINICAL SPECTRUM AND RISK-FACTORS [J].
BOCHUD, PY ;
EGGIMAN, P ;
CALANDRA, T ;
VANMELLE, G ;
SAGHAFI, L ;
FRANCIOLI, P .
CLINICAL INFECTIOUS DISEASES, 1994, 18 (01) :25-31
[2]   ANTI-MICROBIAL SUSCEPTIBILITIES OF SPECIES OF VIRIDANS STREPTOCOCCI [J].
BOURGAULT, AM ;
WILSON, WR ;
WASHINGTON, JA .
JOURNAL OF INFECTIOUS DISEASES, 1979, 140 (03) :316-321
[3]   PREVENTION OF BACTERIAL-ENDOCARDITIS - RECOMMENDATIONS BY THE AMERICAN-HEART-ASSOCIATION [J].
DAJANI, AS ;
BISNO, AL ;
CHUNG, KJ ;
DURACK, DT ;
FREED, M ;
GERBER, MA ;
KARCHMER, AW ;
MILLARD, HD ;
RAHIMTOOLA, S ;
SHULMAN, ST ;
WATANAKUNAKORN, C ;
TAUBERT, KA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 264 (22) :2919-2922
[4]  
HENSLEE J, 1984, LANCET, V1, P393
[5]   ANTIMICROBIAL SUSCEPTIBILITY OF VIRIDANS GROUP STREPTOCOCCI ISOLATED FROM PATIENTS WITH ACUTE-LEUKEMIA RECEIVING OFLOXACIN FOR ANTIBACTERIAL PROPHYLAXIS [J].
KERN, W ;
LINZMEIER, K ;
KURRLE, E .
INFECTION, 1989, 17 (06) :396-397
[6]   STREPTOCOCCAL BACTEREMIA IN ADULT PATIENTS WITH LEUKEMIA UNDERGOING AGGRESSIVE CHEMOTHERAPY - A REVIEW OF 55 CASES [J].
KERN, W ;
KURRLE, E ;
SCHMEISER, T .
INFECTION, 1990, 18 (03) :138-145
[7]   STREPTOCOCCUS-MITIS AND ARDS IN NEUTROPENIC PATIENTS [J].
MCWHINNEY, PHM ;
GILLESPIE, SH ;
KIBBLER, CC ;
HOFFBRAND, AV ;
PRENTICE, HG .
LANCET, 1991, 337 (8738) :429-429
[8]   ACTIVITIES OF POTENTIAL THERAPEUTIC AND PROPHYLACTIC ANTIBIOTICS AGAINST BLOOD CULTURE ISOLATES OF VIRIDANS GROUP STREPTOCOCCI FROM NEUTROPENIC PATIENTS RECEIVING CIPROFLOXACIN [J].
MCWHINNEY, PHM ;
PATEL, S ;
WHILEY, RA ;
HARDIE, JM ;
GILLESPIE, SH ;
KIBBLER, CC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (11) :2493-2495
[9]  
*NAT COMM CLIN LAB, 1995, M100S6 NAT COMM CLIN
[10]  
National Committee for Clinical Laboratory Standards, 1993, METH DIL ANT SUSC TE